[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-iiia-non-small-cell-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-iiia-non-small-cell-lung-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100452129","pathological-response-after-neoadjuvant-treatment-on-nsclc-100452129",false,"NCT05167487","Pathological Response After Neoadjuvant Treatment on NSCLC","Retrospective Observational Study of Resectable Stage IIIA Non-small Cell Lung Cancer Patients: Pathological Response After Neoadjuvant Treatment and Patient Outcomes","PLANET","Inclusion Criteria:\n\n* Patients with resectable stage IIIA disease (according to American Joint Committee on Cancer \\[AJCC\\] lung cancer edition 7 or 8) who were included in the Tumor Thoracic Registry data base and in stage IIIA clinical trials which the sponsor is Fundación GECP.\n* Patients with histologically N2 involvement confirmed\n* Patients diagnosed as stage IIIA from 2010 and 2017\n* Patients who have received neoadjuvant platinum-based treatment and surgery\n* Age ≥ 18 years at time of study entry\n* PET \u002FTC at diagnosis\n\nExclusion Criteria:\n\n* Patients who received chemoradiotherapy neoadjuvant treatment\n* Patients who were not resected after neoadjuvant treatment\n* Patients who were diagnosed after June 2017","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical trials case report forms.",[25],"Stage IIIA Non-small Cell Lung Cancer",[27,28,29,30,31],"Neoadjuvant Treatment","Observational study","Resectable IIIA patients","Non small cell lung cancer","Pathological response","RECRUITING","2026-02-04",{"date":35,"type":36},"2026-02-06","ACTUAL",{"date":38,"type":36},"2021-12-13",{"date":40,"type":21},"2028-12-01",{"name":42,"class":43},"Fundación GECP","OTHER",17,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100596319","phase-2-pank-003-cell-injection-combined-with-standard-adjuvant-chemotherapy-after-surgery-in-patients-with-stage-iiia-nsclc-100596319","NCT07043907","PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC","A Single-center, Single-arm Exploratory Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Voluntarily participate in the clinical trial; fully understand and be informed about this study and sign the informed consent form;\n2. At the time of screening, the age should be between 18 and 75 years old (inclusive), regardless of gender;\n3. Patients with histologically confirmed stage IIIA NSCLC (T4N0M0, T3-4N1M0, T1a-2bN2M0) who underwent R0 resection and received postoperative adjuvant chemotherapy (Exclusion of EGFR sensitizing mutations and ALK fusion); and who received the first dose of PANK-003 cell injection combined with postoperative adjuvant chemotherapy within 8 weeks after radical surgery.;\n4. At the time of enrollment, the expected survival time is more than 6 Months;\n5. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1;\n6. At the time of screening, the laboratory tests should meet the following requirements:\n\n   * White blood cell count ≥ 3.0×10⁹\u002FL;\n   * Neutrophil count ≥ 1.5×10⁹\u002FL;\n   * Lymphocyte count ≥ 0.5×10⁹\u002FL;\n   * Hemoglobin ≥ 90 g\u002FL;\n   * Platelets ≥ 75×10⁹\u002FL;\n   * Serum total bilirubin ≤ 2.0 × ULN (Upper Limit of Normal); for patients with a history\u002Fsuspected Gilbert's syndrome, total bilirubin (TBIL) must be ≤ 3 × ULN.\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN;\n   * Creatinine \\\u003C 1.5×ULN and endogenous creatinine clearance rate ≥ 50 mL\u002Fminute (Cockcroft-Gault method for calculating creatinine clearance rate: For men, creatinine clearance rate = \\[(140 - age) × body weight (kg)\\] \u002F \\[0.818 × creatinine (μmol\u002FL)\\]; For women, creatinine clearance rate = \\[(140 - age) × body weight (kg) × 0.85\\] \u002F \\[0.818 × creatinine (μmol\u002FL)\\]).\n7. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and be willing to use medically recognized highly effective contraception during the study and for at least 1 year after the last study treatment; male subjects with partners of childbearing potential must have undergone surgical sterilization or agree to use effective contraception during the study and for at least 1 year after the last study treatment;\n8. Investigator-confirmed eligibility for study enrollment.\n\nExclusion Criteria:\n\n1. NSCLC patients who have received neoadjuvant therapy;\n2. Pregnant or lactating women;\n3. History of other malignancies, except:\n\n   * Cured non-melanoma skin cancer\n   * Carcinoma in situ of the cervix\n   * Localized prostate cancer\n   * Superficial bladder cancer\n   * Other malignancies with disease-free survival \\>5 years;\n4. Positive virology serology meeting any of:\n\n   * HBsAg(+) and\u002For HBeAg(+) with HBe-Ab(+) and\u002For HBc-Ab(+) and HBV-DNA \\> lower limit of quantification\n   * HCV-Ab(+)\n   * TP-Ab(+)\n   * HIV-Ab(+);\n5. Received investigational drugs or other cell-based immunotherapy within 28 days before screening;\n6. Administration of live\u002Fattenuated vaccines within 4 weeks prior to NK cell infusion;\n7. Medical conditions requiring systemic corticosteroid therapy or other immunosuppressive drug treatments during the study period as determined by the investigator;\n8. Hypersensitivity to:\n\n   * Any component of NK cell products (including serum albumin)\n   * Common emergency medications or anesthetics;\n9. Unstable cardiovascular diseases within 180 days pre-screening, including:\n\n   * Unstable angina\n   * Myocardial infarction\n   * Heart failure (NYHA class ≥III)\n   * Severe arrhythmia requiring medication\n   * Cardiac angioplasty, coronary stenting, or CABG;\n10. Any condition that may compromise protocol compliance or patient safety as determined by the investigator:\n\n    * Poorly controlled diabetes\n    * Uncontrolled infections\n    * Central nervous system disorders\n    * Bleeding\u002Fthrombotic diathesis\n    * Poor compliance\n    * Substance abuse.","75 Years",{"count":54,"type":21},115,"INTERVENTIONAL",[57],"PHASE2","A Single-center, Single-arm Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Stage IIIA Non-Small Cell Lung Cancer",[25],"NOT_YET_RECRUITING","2025-06-29",{"date":63,"type":36},"2025-07-01",{"date":65,"type":21},"2025-07-08",{"date":67,"type":21},"2029-06-18",{"name":69,"class":70},"Shenzhen Celconta Life Science Co., Ltd.","INDUSTRY",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":4,"leadSponsor":91,"locationsCount":94},"100178275","biomarkers-in-predicting-treatment-response-in-samples-from-patients-with-early-stage-non-small-cell-lung-cancer-previously-treated-with-adjuvant-chemotherapy-100178275","NCT01595074","Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy","The Identification, Validation and Implemention of Prognostic and\u002For Predictive Biomarkers for Adjuvant Chemotherapy in Early Stage Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n* Samples from patients treated in 4 adjuvant chemotherapy (ACT) for early-stage non-small cell lung cancer (NSCLC) pivotal trials:\n\n  * International Adjuvant Lung Cancer Trail (IALT)\n  * Cancer and Leukemia Group B (CALGB)-9633\n  * CAN-NCIC-BR10\n  * Adjuvant Navelbine International Trialist Association (ANITA)\n* Not specified\n* See Disease Characteristics",{"count":79,"type":21},950,"This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.",[82,83,84,85,25],"Stage IA Non-small Cell Lung Cancer","Stage IB Non-small Cell Lung Cancer","Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","2013-09-19",{"date":88,"type":21},"2013-09-20",{"date":90,"type":4},"2012-05",{"name":92,"class":93},"National Cancer Institute (NCI)","NIH",1]